Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore
Mankind Pharma set out an expansion in a quarterly results development.
· Economic Times Markets, ET Stocks
Mankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, supported by domestic and export growth, while EBITDA margins expanded 210 basis points.
The analysis
Mankind Pharma reported Rs 716 crore, with movement of 8%, 38% and 17% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.9% on the day at ₹2,492.80, and has returned -3.2% over three months. It sits 5% below its 52-week high. The pharma & healthcare sector has moved -0.9% over the same period, so Mankind Pharma is running 2.3 points behind its peers.
For Mankind Pharma, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Mankind Pharma (MANKIND), in Pharma & Healthcare.
- Over three months: Mankind Pharma -3.2% against Pharma & Healthcare -0.9% (2.3 points behind).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Mankind PharmaMANKIND · Pharma & Healthcare | ₹2,492.80 | +0.9% | -0.4% | -3.2% | -4.8% | 1.0× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Mankind Pharma
Prices as of 30 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Max Healthcare Q2 net profit falls 15.6% on higher operating, tax expenses
Max Healthcare Q2 PAT rises 10% to ₹448 cr on higher bed occupancy